Cargando…

Risk factors of distant brain failure for patients with newly diagnosed brain metastases treated with stereotactic radiotherapy alone

OBJECTIVE: To explore the risk factors of distant brain failure (DBF) for patients with brain metastasis (BM) who were treated with stereotactic radiotherapy alone and to group the patients on the basis of their risk levels. METHODS AND MATERIALS: We retrospectively analyzed 132 newly diagnosed BM p...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiu-jun, Xiao, Jian-ping, Li, Xiang-pan, Jiang, Xue-song, Zhang, Ye, Xu, Ying-jie, Dai, Jian-rong, Li, Ye-xiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3274494/
https://www.ncbi.nlm.nih.gov/pubmed/22182786
http://dx.doi.org/10.1186/1748-717X-6-175
_version_ 1782223079768850432
author Chen, Xiu-jun
Xiao, Jian-ping
Li, Xiang-pan
Jiang, Xue-song
Zhang, Ye
Xu, Ying-jie
Dai, Jian-rong
Li, Ye-xiong
author_facet Chen, Xiu-jun
Xiao, Jian-ping
Li, Xiang-pan
Jiang, Xue-song
Zhang, Ye
Xu, Ying-jie
Dai, Jian-rong
Li, Ye-xiong
author_sort Chen, Xiu-jun
collection PubMed
description OBJECTIVE: To explore the risk factors of distant brain failure (DBF) for patients with brain metastasis (BM) who were treated with stereotactic radiotherapy alone and to group the patients on the basis of their risk levels. METHODS AND MATERIALS: We retrospectively analyzed 132 newly diagnosed BM patients who were treated with stereotactic radiotherapy alone from May 2000 to April 2010. Kaplan-Meier and Cox proportional hazards regression analyses were performed for univariate and multivariate analyses. RESULTS: The 1-year incidence rate of DBF was 44.7%, and the median DBF time (MDBFT) was 18 months. In multivariate analysis, the risk factors of DBF were the number of BMs greater than 1 (p = 0.041), uncontrolled extracranial disease (p = 0.005), interval time (IT) of less than 60 months between the diagnosis of primary tumor and BM (p = 0.024), and total volume of BM was greater than 6 cc (p = 0.049). Each risk factor was assigned 1 score. The median survival times for the patients with scores of 0-1, 2-3, and 4 were 31, 12, and 10 months, respectively, and the corresponding MDBFTs were not reached, 13, and 3 months, respectively, (p < 0.001). The crude DBF incidence rates in patients with scores of 0-1, 2-3, and 4 were 14.8%, 50.0%, and 76.9%, respectively, (p < 0.001). CONCLUSIONS: The patients with scores of 0-1 had a lower risk of DBF than the patients with higher scores did, and it may be reasonable to treat these patients with SRS alone and resort to whole-brain radiation therapy only for salvage. The patients with a score of 4 had the highest risk of developing DBF after stereotactic radiotherapy alone, these patients may be candidates for initial whole-brain radiation therapy or clinical trials. The patients with a score of 2-3 had a moderate risk of developing DBF, SRT alone combined with close clinical monitoring would be the optimal treatment regimen for such patients, and for those patients with difficulties in receiving close clinical mornitoring, SRT combined with WBRT will be more suitable.
format Online
Article
Text
id pubmed-3274494
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32744942012-02-08 Risk factors of distant brain failure for patients with newly diagnosed brain metastases treated with stereotactic radiotherapy alone Chen, Xiu-jun Xiao, Jian-ping Li, Xiang-pan Jiang, Xue-song Zhang, Ye Xu, Ying-jie Dai, Jian-rong Li, Ye-xiong Radiat Oncol Research OBJECTIVE: To explore the risk factors of distant brain failure (DBF) for patients with brain metastasis (BM) who were treated with stereotactic radiotherapy alone and to group the patients on the basis of their risk levels. METHODS AND MATERIALS: We retrospectively analyzed 132 newly diagnosed BM patients who were treated with stereotactic radiotherapy alone from May 2000 to April 2010. Kaplan-Meier and Cox proportional hazards regression analyses were performed for univariate and multivariate analyses. RESULTS: The 1-year incidence rate of DBF was 44.7%, and the median DBF time (MDBFT) was 18 months. In multivariate analysis, the risk factors of DBF were the number of BMs greater than 1 (p = 0.041), uncontrolled extracranial disease (p = 0.005), interval time (IT) of less than 60 months between the diagnosis of primary tumor and BM (p = 0.024), and total volume of BM was greater than 6 cc (p = 0.049). Each risk factor was assigned 1 score. The median survival times for the patients with scores of 0-1, 2-3, and 4 were 31, 12, and 10 months, respectively, and the corresponding MDBFTs were not reached, 13, and 3 months, respectively, (p < 0.001). The crude DBF incidence rates in patients with scores of 0-1, 2-3, and 4 were 14.8%, 50.0%, and 76.9%, respectively, (p < 0.001). CONCLUSIONS: The patients with scores of 0-1 had a lower risk of DBF than the patients with higher scores did, and it may be reasonable to treat these patients with SRS alone and resort to whole-brain radiation therapy only for salvage. The patients with a score of 4 had the highest risk of developing DBF after stereotactic radiotherapy alone, these patients may be candidates for initial whole-brain radiation therapy or clinical trials. The patients with a score of 2-3 had a moderate risk of developing DBF, SRT alone combined with close clinical monitoring would be the optimal treatment regimen for such patients, and for those patients with difficulties in receiving close clinical mornitoring, SRT combined with WBRT will be more suitable. BioMed Central 2011-12-19 /pmc/articles/PMC3274494/ /pubmed/22182786 http://dx.doi.org/10.1186/1748-717X-6-175 Text en Copyright ©2011 Chen et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Chen, Xiu-jun
Xiao, Jian-ping
Li, Xiang-pan
Jiang, Xue-song
Zhang, Ye
Xu, Ying-jie
Dai, Jian-rong
Li, Ye-xiong
Risk factors of distant brain failure for patients with newly diagnosed brain metastases treated with stereotactic radiotherapy alone
title Risk factors of distant brain failure for patients with newly diagnosed brain metastases treated with stereotactic radiotherapy alone
title_full Risk factors of distant brain failure for patients with newly diagnosed brain metastases treated with stereotactic radiotherapy alone
title_fullStr Risk factors of distant brain failure for patients with newly diagnosed brain metastases treated with stereotactic radiotherapy alone
title_full_unstemmed Risk factors of distant brain failure for patients with newly diagnosed brain metastases treated with stereotactic radiotherapy alone
title_short Risk factors of distant brain failure for patients with newly diagnosed brain metastases treated with stereotactic radiotherapy alone
title_sort risk factors of distant brain failure for patients with newly diagnosed brain metastases treated with stereotactic radiotherapy alone
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3274494/
https://www.ncbi.nlm.nih.gov/pubmed/22182786
http://dx.doi.org/10.1186/1748-717X-6-175
work_keys_str_mv AT chenxiujun riskfactorsofdistantbrainfailureforpatientswithnewlydiagnosedbrainmetastasestreatedwithstereotacticradiotherapyalone
AT xiaojianping riskfactorsofdistantbrainfailureforpatientswithnewlydiagnosedbrainmetastasestreatedwithstereotacticradiotherapyalone
AT lixiangpan riskfactorsofdistantbrainfailureforpatientswithnewlydiagnosedbrainmetastasestreatedwithstereotacticradiotherapyalone
AT jiangxuesong riskfactorsofdistantbrainfailureforpatientswithnewlydiagnosedbrainmetastasestreatedwithstereotacticradiotherapyalone
AT zhangye riskfactorsofdistantbrainfailureforpatientswithnewlydiagnosedbrainmetastasestreatedwithstereotacticradiotherapyalone
AT xuyingjie riskfactorsofdistantbrainfailureforpatientswithnewlydiagnosedbrainmetastasestreatedwithstereotacticradiotherapyalone
AT daijianrong riskfactorsofdistantbrainfailureforpatientswithnewlydiagnosedbrainmetastasestreatedwithstereotacticradiotherapyalone
AT liyexiong riskfactorsofdistantbrainfailureforpatientswithnewlydiagnosedbrainmetastasestreatedwithstereotacticradiotherapyalone